Utility approach to measuring health-related quality of life

Torrance, George W.

doi:10.1016/0021-9681(87)90019-1

Cited by 955 publications

(536 citation statements)

References 21 publications

Supporting

Mentioning

501

Contrasting

Unclassified

Order By: Relevance

“…Quality-adjusted life year (QALY), a most frequently used health status index, combines information on the length of life (quantity) and the QoL, where the latter is measured by utilities on a scale that has values of 1 and 0 respectively for full health and death (67). The unit QALY is therefore defined as 1 year of life with full health (68). In the theoretical basis for QALY provided by Torrance, full health was defined as 'perfect functioning'.…”

Section: Qol Measurement For Use In Pharmacoeconomic Evaluationsmentioning

confidence: 99%

Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

Kołtowska-Häggström¹,

Mattsson²,

Shalet³

2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.

show abstract

Section: Qol Measurement For Use In Pharmacoeconomic Evaluationsmentioning

confidence: 99%

Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

Kołtowska-Häggström¹,

Mattsson²,

Shalet³

2009

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…By definition, perfect health has a utility score of 1, and death has a utility score of 0. Several methods are available to estimate utilities, including the standard gamble [7,63,94,95], VASs [33,75,96], multiattribute scales (eg, SF-6D, EQ-5D [formerly known as the EuroQol], Health Utilities Index) [9,10,29,31,34,97], and the time trade-off [33,75,94,96].…”

Section: Conventional Clinical Research Versus Promsmentioning

confidence: 99%

Stakeholders in Outcome Measures: Review From a Clinical Perspective

Brinker

O’Connor

2013

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…A utility is a numerical measure of a preference for a health state and ranges in score from zero to 1. 25 The TTO, as originally proposed by Torrance et al, 26 asks the participant to compare 2 prospects: the health state of interest, which lasts for X years, and perfect health, which lasts for a shorter period (Y years). The TTO is a comparison between X years in a health state and Y<X years in ''perfect health.''…”

Section: Time Trade-off Techniquementioning

confidence: 99%

Sex or survival

Wilke

Krahn

Tomlinson

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Combined long-term androgen deprivation (LTAD) and radiation conveys a prostate cancer-specific survival advantage over combined short-term androgen deprivation (STAD) and radiation. The seminal question is whether or not the gains are worth the adverse effects of LTAD with respect to patient preferences. METHODS: Preferences for LTAD compared with STAD were elicited by direct patient interview using the probability trade-off method. ''Time trade-off utilities'' (TTOu) for erectile dysfunction and osteoporosis were elicited using the time tradeoff method. Participants' current prostate cancer-specific health state was assessed using the Patient-Oriented Prostate Utility Scale-Psychometric. Participants' current sexual function was assessed using the International Index of Erectile Function (IIEF). RESULTS: All participants were willing to trade survival rather than undergo LTAD compared with STAD. The mean minimally required increment in prostate cancer-specific survival (MRIS) was 8.2%. The mean TTOu for impotence was 0.78, and the mean TTOu for osteoporosis was 0.71. The MRIS was correlated with the Sexual Desire domain score of the IIEF (Spearman rank-correlation coefficient, r ¼ 0.50; P<.0001). CONCLUSIONS: Patients desired more prostate cancer-specific survival than what was afforded by LTAD and radiotherapy compared with STAD and radiotherapy.

show abstract

Utility approach to measuring health-related quality of life

Cited by 955 publications

References 21 publications

Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

Stakeholders in Outcome Measures: Review From a Clinical Perspective

Sex or survival

Contact Info

Product

Resources

About